11/14/2018
Name:Jennifer Robinson Diamond, M.D.
Current Position: Assistant Professor of Medicine
Developmental Therapeutics and Breast Oncology Programs
University of Colorado Denver School of Medicine
Department of Medicine
Division of Oncology
Work Address: University of Colorado Cancer Center
Mail Stop 8117
12801 E. 17th Avenue
Room 8123, RC -1 South
Aurora, CO 80045
Phone: (303) 724-5499
FAX: (303) 724-3889
E-mail:
Education:
1995-2000Univ. of Arizona, Tucson, AZB. A.Biochemistry
2000-2004Univ. of Arizona College of MedicineM.D.Medicine
Postdoctoral Training:
2004-2007:Residency, Internal Medicine, University of Colorado Health Sciences Center, Denver, CO. Robert Anderson, M.D., Chair.
2007-2010:Fellowship in Medical Oncology, Department of Oncology. University of Colorado Health Sciences Center, Denver, CO. S. Gail Eckhardt, M.D., Chair.
Academic Appointments:
2010-Present:Assistant Professor, Department of Medicine, Division of Oncology; University of Colorado Denver, Aurora, CO.
Hospital and Other Professional Appointments:
2010-Present:Associate Member, University of Colorado Comprehensive Cancer Center, University of Colorado Denver, Aurora, CO.
Licensure and Board Certification:
2007-Present:Colorado, State Medical License
2007:American Board of Internal Medicine, Diplomat, Internal Medicine
2010: American Board of Internal Medicine, Diplomat, Medical Oncology - pending
Professional Organization Membership:
2009:Member, American Association for Cancer Research
2009:Member, American Society of Clinical Oncology
Awards and Honors:
1998:Phi Beta Kappa
1998:Golden Key National Honor Society
1999:Phi Eta Sigma
1998: International Scholar, Biophysical Chemistry, University of Uppsala, Sweden
2000: Biomedical Research Abroad Vistas Open (BRAVO) International Scholar, Tubingen, Germany
2000-2004: Jeremiah Metzger Scholarship
2000-2004:Robert F. Allen Memorial Scholarship
2004:Alpha Omega Alpha
2004:University of Arizona College of Medicine Excellence in Research Award
2004:American Medical Women’s Association, Glasgow-Rubin Achievement Citation
2008:Travel award recipient, 10th Annual Lynn Sage Breast Cancer Symposium, Chicago, IL
2009: Selected Participant, CEC Workshop on Clinical Pharmacology of Anticancer Agents, Washington D.C.
2009: Selected Participant, ASCO/AACR Workshop on Methods in Clinical Cancer Research, Vail, CO
2008-2010:NIH T32 Training Grant Recipient
Major Committee and Service Responsibilities:
UCD
2006-2007Curriculum Committee, Internal Medicine Residency
2008-2009Housestaff Association Executive Committee Member
2008-2009Board of Directors, Graduate Medical Education Health Benefits
2008-Present: Internal Medicine Residency Selection Committee
2009-Present:Oncology Fellowship Selection Committee
Review and Referee Work:
Journal Reviewer
2010: Onkologie (ad hoc)
Invited Lectures and Presentations:
2002:Western Federation for Medical Research (WFMR) Regional Meeting, Quantification of Circulating Endothelial Cells in Cancer Patients. Carmel, CA
2007:American College of Physicians Local Chapter Meeting, Tick-Borne Relapsing Fever: Therapy Worse than Initial Illness, Denver, CO
2009: 11th Annual Symposium on Anti-Angiogenic Agents, Simultaneous Targeting of Aurora A and VEGF Pathways. La Jolla, CA
2009:University of Colorado Cancer Center Colorado Cancer Day, Introduction to Clinical trials, Denver, CO
Teaching Record:
House Staff/Fellows Presentation
2010-Present:UCD, Medical Oncology, Breast Cancer (Oncology Fellows)
Undergraduates/ Graduate Student Presentation
2009-Present:UCD, Cancer Pharmacology Course, Breast Cancer
Bilbliography:
Manuscripts:
2002:Weinstein R, Eleid N, LeCesne C, Durando B, Crawford JT, Heffner M, Layton C, O’Keefe M, Robinson J, Rudinsky S, Henriksen EJ, Tischler ME. Differential Half-Maximal Effects of Human Insulin and Its Analogs for In Situ Glucose Transport and Protein Synthesis in Rat Soleus Muscle. Metabolism 2002:51;1065-1070.
2009:Diamond JR, Finlayson C, Borges VF. Hepatic Complications of Breast Cancer. Lancet Oncology 2009:10;615-621.
2009:Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardestry L, Barbour L, Klein C, Rabinovitch R, Elias A, Borges VF. Early stage BRCA-2 associated breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state. Oncology 2009:23;784-791.
2009:Diamond JR, Borges VF, Eckhardt SG, Jimeno A. BRCA in breast cancer: from risk assessment to therapeutic prediction. Drug News Perspect 2009:22;603-608.
2010:Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010:16;2989-98.
2010: Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak E, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor CF, Messersmith WA, Shapiro GI. Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2010 Dec 3 [epub ahead of print].
2010: Kounalakis N, Diamond J, Rusthoven K, Horn W, Jindal S, Wisell J, Klein C, Elias A, Finlayson C, Borges VF. A young women presenting with pleomorphic lobular carcinoma in situ on core biopsy is subsequently diagnosed with invasive lobular carcinoma. Oncology 2010: in press.
Abstracts:
Renn W, Robinson J, Stumvall M, Fritsche A, Wahl HG, Häring H-U, Jacob S. A Minimal
Model For the Insulin-Mediated Regulation of Lipolysis. The 6th Symposium on Computers in Diabetes in Herzliya, Israel, Diabetes, Nutrition, and Metabolism Clinical and Experimental 2000:13;240.
Robinson JS, Iannone M, Seaver N, Stopeck AT. Quantification of Circulating Endothelial Cells in Cancer Patients. Journal of Investigative Medicine 2002:50:80A.
Diamond JR, Eckhardt SG, Pitts TM, Britt BC, Kachaeva MI, Varella-Garcia M, Bray MR, Fletcher GC, Tentler JJ. A novel multi-targeted Aurora A and VEGFR2 kinase inhibitor, ENMD-2076, demonstrates synergistic antiproliferative and proapoptotic effects in combination with chemotherapy and trastuzumab in breast cancer cell lines. Molecular Targets and Cancer Therapeutics of the AACR-NCI-EORTC International Conference. Boston MA. 2009.
Diamond JR, Amaria R, O’Donnell CI, Meltesen L, Swisshelm K, Melancon D, McGavran L, Singh M, Elias A, Borges VF. The incidence of low-level HER2 gene amplification and chromosome 17 polysomy in cases of newly diagnosed breast cancer and their association with clinical prognostic markers. J Clin Oncol. Vol 27, abstr e22012, 2009.
Bastos BR, Diamond J, Hansen R, Gustafson D, Arnott J, Bray M, Sidor C, Messersmith W, Shapiro G. An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer. J Clin Oncol.Vol 27, abstr 3520, 2009.
Selby H, Kim J, Tentler T, Diamond J, Pitts T, Leong S, Messersmith W, Jimeno A, Eckhardt SG, Tan AC. A Bioinformatics strategy to accelerate the development of predictive biomarkers for novel anti-cancer agents. Intelligence Systems for Molecular Biology (ISMB). Boston MA. 2010.